Surgical Re-Resection for Isolated Local Recurrence of Pancreatic Cancer: A CaseSeries of 3 Patients and Literature Review
DOI:
https://doi.org/10.5644/ama2006-124.495Keywords:
Pancreatectomy, Pancreatic Neoplasms, Repeat SurgeryAbstract
Objective. This retrospective case series study aims to assess the clinical role of surgical re-resection for isolated local recurrence of pancreatic cancer, integrating detailed case presentations with current evidence to clarify patient selection criteria, operative feasibility, and oncologic outcomes.
Case Presentations. We present three patients with locally recurrent pancreatic cancer who underwent repeat pancreatic resection. Patient 1, who previously underwent distal pancreatectomy for an Intraductal Papillary Mucinous Neoplasm (IPMN)-associated adenocarcinoma, developed a new pancreatic head lesion three years later and under- went pylorus-preserving pancreaticoduodenectomy; histopathology confirmed a small invasive IPMN, and the patient remains alive 8 years after the initial diagnosis and 5 years after the reoperation. Patient 2, who had previously undergone Pylorus-Preserving Pancreaticoduodenectomy for distal bile duct adenocarcinoma, developed recurrent disease in the pancreatic body and tail three years later. He underwent distal pancreatectomy but developed liver recurrence due to hematogenous metastasis one month postoperatively and succumbed 6 months later from generalized widespread disease. Patient 3, who previously un- derwent a Whipple procedure for IPMN-associated adenocarcinoma, developed a recurrent mass at the pancreatojejunostomy five years later and underwent distal pancreatectomy, with an uneventful recovery.
Conclusion. Our findings suggest that repeat pancreatic resection may be feasible in carefully selected patients with isolated local recurrence, potentially offering a survival benefit. Strict selection criteria, including the absence of distant metastases, good performance status, and technically resect- able disease, appear essential to optimize outcomes, supporting the consideration of surgical re-resection as an option within a multidisciplinary management framework.
References
Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(8):1083-93. doi: 10.6004/jnccn.2014.0106.
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
Kleeff J, Reiser C, Hinz U, Bachmann J, Debus J, Jaeger D, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245(4):566-72. doi: 10.1097/01. sla.0000245845.06772.7d.
Moletta L, Serafini S, Valmasoni M, Pierobon ES, Ponzoni A, Sperti C. Surgery for Recurrent Pancreatic Cancer: Is It Effective? Cancers (Basel). 2019;11(7):991. doi: 10.3390/ cancers11070991.
Sperti C, Moletta L, Merigliano S. Multimodality treatment of recurrent pancreatic cancer: Mith or reality? World J Gastrointest Oncol. 2015;7(12):375-82. doi: 10.4251/wjgo.v7.i12.375.
Nienhüser H, Büchler MW, Schneider M. Resection of Recurrent Pancreatic Cancer: Who Can Benefit? Visc Med. 2022;38(1):42-8. doi: 10.1159/000519754. Epub 2021 Nov 11.
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-10. doi: 10.1056/NEJMoa032295. Erratum in: N Engl J Med. 2004;351(7):726.
Okusaka T. Treatment for postoperative recurrence of pancreatic cancer: a narrative review. Chin Clin Oncol. 2022;11(3):19. doi: 10.21037/cco-21-87. Epub 2022 Jun 2.
Groot VP, van Santvoort HC, Rombouts SJ, Hagendoorn J, Borel Rinkes IH, van Vulpen M, et al. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB (Oxford). 2017;19(2):83-92. doi: 10.1016/j. hpb.2016.11.001. Epub 2017 Jan 3.
Hajibandeh S, Hajibandeh S, Evans D, Athwal TS. Metaanalysis of pancreatic re-resection for locally recurrent pancreatic cancer following index pancreatectomy. Ann Hepatobiliary Pancreat Surg. 2024;28(3):315-24. doi: 10.14701/ahbps.24-041. Epub 2024 May 28.
Reddy JR, Saxena R, Singh RK, Pottakkat B, Prakash A, Behari A, et al. Reoperation following Pancreaticoduodenectomy. Int J Surg Oncol. 2012;2012:218248. doi: 10.1155/2012/218248. Epub 2012 Sep 12.
Choi M, Kim NW, Hwang HK, Lee WJ, Kang CM. Repeated Pancreatectomy for Isolated Local Recurrence in the Remnant Pancreas Following Radical Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Pooled Analysis. J Clin Med. 2020;9(12):3945. doi: 10.3390/jcm9123945.
Serafini S, Sperti C, Friziero A, Brazzale AR, Buratin A, Ponzoni A, et al. Systematic Review and Meta-Analysis of Surgical Treatment for Isolated Local Recurrence of Pancreatic Cancer. Cancers (Basel). 2021;13(6):1277. doi: 10.3390/cancers13061277.
Miyazaki M, Yoshitomi H, Shimizu H, Ohtsuka M, Yoshidome H, Furukawa K, et al. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery. 2014;155(1):58-66. doi: 10.1016/j.surg.2013.06.050. Epub 2013 Nov 12.
Yamada S, Kobayashi A, Nakamori S, Baba H, Yamamoto M, Yamaue H, et al. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-BiliaryPancreatic Surgery. Surgery. 2018;164(5):1049-56. doi: 10.1016/j.surg.2018.05.050. Epub 2018 Jul 29.
Kim YI, Song KB, Lee YJ, Park KM, Hwang DW, Lee JH, et al. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg. 2019;106(7):898-909. doi: 10.1002/bjs.11144.
Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20(3):964-72. doi: 10.1245/s10434-012-2762-z. Epub 2012 Dec 12.
Zhou Y, Song A, Wu L, Si X, Li Y. Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis. Pancreatology. 2016;16(6):1124-8. doi: 10.1016/j.pan.2016.09.015. Epub 2016 Sep 29.
Yopp AC, Katabi N, Janakos M, Klimstra DS, D‘Angelica MI, DeMatteo RP, et al. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011;253(5):968-74. doi: 10.1097/SLA.0b013e318214bcb4.
Hashimoto D, Chikamoto A, Ohmuraya M, Sakata K, Miyake K, Kuroki H, et al. Pancreatic cancer in the remnant pancreas following primary pancreatic resection. Surg Today. 2014;44(7):1313-20. doi: 10.1007/s00595-013-0708-0. Epub 2013 Aug 22.
Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(3):e105-15. doi: 10.1016/S1470-2045(22)00066-3.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Spiros Delis, Nikolaos Taprantzis, Dimosthenis Chrysikos, Amir Shihada, Theodore Troupis
This work is licensed under a Creative Commons Attribution 4.0 International License.
